Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1268 articles with Regeneron Pharmaceuticals, Inc.
-
Regeneron Elects Dr. Craig B. Thompson to Board of Directors
10/3/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that Craig B. Thompson , M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board.
-
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
9/30/2022
Regeneron Pharmaceuticals, Inc. announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® Injection, in patients with diabetic macular edema and wet age-related macular degeneration.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.
-
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
9/28/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent® for the treatment of adult patients with prurigo nodularis.
-
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
9/28/2022
The U.S. Food and Drug Administration has approved Dupixent® for the treatment of adult patients with prurigo nodularis.
-
The FDA might only have two PDUFA dates on the calendar this week, but all eyes in the neurodegenerative disease community will be on the first one: Amylyx's AMX0035 for ALS.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
Employee Resource Groups (ERGs) can be an asset to any successful Diversity, Equity and Inclusion (DEI) initiative, as long as they are given the proper resources and guidance.
-
The FDA has two PDUFA dates on its calendar this week, with two extra days slotted for an advisory committee meeting to evaluate drug applications from three companies.
-
Intellia Therapeutics reported early, positive signs from its in vivo gene therapies for both transthyretin (ATTR) amyloidosis and hereditary angioedema Friday.
-
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
9/16/2022
Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis.
-
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
9/15/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3 Dupixent® (dupilumab) trial in children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.
-
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
9/15/2022
Regeneron Pharmaceuticals (Nasdaq: REGN ) and Alnylam Pharmaceuticals, Inc. announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).
-
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
9/15/2022
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) and Regeneron Pharmaceuticals (Nasdaq: REGN ) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH).
-
There's a new collaboration in the Parkinson's disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
-
BMS validated LAG-3 as the newest checkpoint in immuno-oncology in March. Regeneron, Merck and Immutep S.A. have been working hard to develop the next successful LAG-3 inhibitor.
-
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
-
Regeneron’s oncology strategy is centered around improving checkpoint inhibitor treatments with combination therapies, according to a pipeline overview presented Monday morning.
-
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
9/12/2022
Regeneron Pharmaceuticals, Inc. announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.